PT  - JOURNAL ARTICLE
AU  - Andreassen, Maren M. Sjaastad
AU  - Rodríguez-Soto, Ana E.
AU  - Conlin, Christopher C.
AU  - Vidić, Igor
AU  - Seibert, Tyler M.
AU  - Wallace, Anne M.
AU  - Zare, Somaye
AU  - Kuperman, Joshua
AU  - Abudu, Boya
AU  - Ahn, Grace S.
AU  - Hahn, Michael
AU  - Jerome, Neil P.
AU  - Østlie, Agnes
AU  - Bathen, Tone F.
AU  - Ojeda-Fournier, Haydee
AU  - Goa, Pål Erik
AU  - Rakow-Penner, Rebecca
AU  - Dale, Anders M.
TI  - Discrimination of breast cancer from healthy breast tissues using a three-component diffusion-weighted MRI model
AID  - 10.1101/2020.09.03.20179481
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.03.20179481
4099  - http://medrxiv.org/content/early/2020/09/04/2020.09.03.20179481.short
4100  - http://medrxiv.org/content/early/2020/09/04/2020.09.03.20179481.full
AB  - Purpose Diffusion-weighted magnetic resonance imaging (DW-MRI) is a contrast-free modality that has demonstrated ability to discriminate between pre-defined benign and malignant breast lesions. However, the ability of DW-MRI to discriminate cancer tissue from all other breast tissues in a clinical setting is unknown. Here we explore the ability to distinguish breast cancer from healthy breast tissues using signal contributions from the newly developed three-component multi-b-value DW-MRI model.Experimental design Pathology-proven breast cancer patients from two datasets (n=81 and n=25) underwent multi-b-value DW-MRI. The three-component signal contributions C1 and C2 and their product, C1C2, were compared to the image defined on maximum b-value (DWImax), conventional apparent diffusion coefficient (ADC), and apparent diffusion kurtosis (Kapp). Ability to discriminate between cancer and healthy breast tissues was assessed by the false positive rate given sensitivity of 80% (FPR80) and receiver operating characteristic (ROC) area under the curve (AUC).Results Mean FPR80 for both datasets was 0.016 (95%CI=0.008-0.024) for C1C2, 0.136 (95%CI=0.092-0.180) for C1, 0.068 (95%CI=0.049-0.087) for C2, 0.159 (95%CI=0.114-0.204) for DWImax, 0.731 (95%CI=0.692–0.770) for ADC and 0.684 (95%CI=0.660-0.709) for Kapp. Mean ROC AUC for C1C2 was 0.984 (95%CI=0.977-0.991).Conclusions The three-component model yields a clinically useful discrimination between cancer and healthy breast tissues, superior to other DW-MRI methods and obliviating pre-defining lesions by radiologists. This novel DW-MRI method may serve as non-contrast alternative to standard-of-care dynamic contrast-enhanced MRI (DCE-MRI); removing the need to administer Gadolinium contrast decreases scan time and any accumulation of Gadolinium in the brain.Competing Interest StatementDr. Dale reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. He receives funding through research grants from GE Healthcare to UCSD. Dr. Rakow-Penner is a consultant for Human Longevity, Inc. and receives funding through research grants from GE Healthcare. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. Dr. Igor Vidić is employed as a consultant for Cortechs Labs, Inc. Dr. Seibert reports personal honoraria in the past three years from Varian Medical Systems, Multimodal Imaging Services Corporation, and WebMD.Funding StatementCalifornia Breast Cancer Research Program Early Career Award, GE Healthcare, Fulbright Scholarship Program, Mid-Norway Regional Health Authority #46084400, University of California Breast Cancer Screening Program #25IB-0056, NIH/NIBIB #K08EB026503.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study 1: UCSD IRB approved retrospective study, need for consent was waived. Study 2: The study was approved by the Regional Committees for Medical and Health Research Ethics (REC Central Norway, 2011/568).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeswe do not have IRB approval to share raw data with general public.